Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

Leukemia. 2007 Aug;21(8):1827-8. doi: 10.1038/sj.leu.2404711. Epub 2007 Apr 26.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 5*
  • Cytogenetic Analysis
  • Female
  • Humans
  • Janus Kinase 2 / genetics*
  • Lenalidomide
  • Male
  • Middle Aged
  • Point Mutation / genetics*
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / genetics
  • Remission Induction
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Antineoplastic Agents
  • Thalidomide
  • JAK2 protein, human
  • Janus Kinase 2
  • Lenalidomide